Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 3, 9, 10, 1, 2, 50 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

Alloksys Life Sciences BV
Am-Pharma BV
Amniotics AB
Anagenics Ltd
Angion Biomedica Corp
Angiotensin Therapeutics Inc
Arch Biopartners Inc
Ashvattha Therapeutics LLC
Axolo Pharma Inc
Balmes Transplantation SAS
Bessor Pharma LLC
CFM Pharma Holding BV
Chaperone Pharma BV
Claritas Pharmaceuticals Inc
Curigin Co Ltd
Cypralis Ltd
DURECT Corp
Evotec SE
Exponential Biotherapies Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
GeneScience Pharmaceuticals Co Ltd
Goldilocks Therapeutics Inc
Guard Therapeutics International AB
Haisco Pharmaceutical Group Co Ltd
HemaFlo Therapeutics Inc
Hybridize Pharma BV
iCELL Biotechnology Co Ltd
ILIAS Biologics Inc
Johnson & Johnson
Kantum Pharma Inc
Klotho Therapeutics Inc
Kringle Pharma Inc
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
Meridigen Biotech Co Ltd
Metro International Biotech LLC
Mission Therapeutics Ltd
Mitobridge Inc
Mitotech SA
Mitotherapeutix LLC
NeoProgen Inc
Nephraegis Therapeutics
Orgenesis Inc
Paranta Biosciences Ltd
Pharmazz Inc
Pharmicell Co Ltd
Pharming Group NV
Praetego Inc
Q BioMed Inc
Radikal Therapeutics Inc
Rediscovery Life Sciences
Renibus Therapeutics Inc
Rui Nuo Medical Technology (Shanghai) Co Ltd
Sentien Biotechnologies Inc
Sidereal Therapeutics Inc
Silver Creek Pharmaceuticals Inc
Slate Bio Inc
STATegics Inc
Sulfateq BV
TES Pharma SRL
TheraSource LLC
Theratome Bio Inc
Unicycive Therapeutics Inc
Unicyte AG
Valo Health LLC
Vasculonics LLC
Vasomune Inc
vasopharm GmbH
Vivoryon Therapeutics NV
Xigen SA
XORTX Therapeutics Inc